Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

Abstract Introduction Spinal cord injury (SCI) is a devastating injury and remains one of the largest medical and social burdens because of its intractable nature. According to the recent advances in stem cell biology, the possibility of spinal cord regeneration and functional restoration has been s...

Full description

Saved in:
Bibliographic Details
Main Authors: Masao Koda, Shiro Imagama, Hiroaki Nakashima, Sadayuki Ito, Naoki Segi, Jun Ouchida, Kota Suda, Satoko Harmon Matsumoto, Miki Komatsu, Toshiki Endo, Shinsuke Suzuki, Satoshi Inami, Haruki Ueda, Masayuki Miyagi, Gen Inoue, Masashi Takaso, Keiji Nagata, Hiroshi Yamada, Naosuke Kamei, Toshio Nakamae, Hidenori Suzuki, Norihiro Nishida, Masahiro Funaba, Gentaro Kumagai, Takeo Furuya, Yu Yamato, Toru Funayama, Hiroshi Takahashi, Masashi Yamazaki
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Stem Cell Research & Therapy
Subjects:
Spinal cord injury
Regenerative therapy
Muse cell
Clinical trial
Online Access:https://doi.org/10.1186/s13287-024-03842-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13287-024-03842-w

Similar Items